PHASE-I CLINICAL-TRIAL WITH ALPHA 1,3,5-TRIGLYCIDYL-S-TRIAZINETRIONE (NSC-296934)

被引：18

作者：

PICCART, M

ROZENCWEIG, M

DODION, P

CUMPS, E

CRESPEIGNE, N

MAKAROFF, O

ATASSI, G

KISNER, D

KENIS, Y

机构：

[1] INST JULES BORDET,SERV MED,B-1000 BRUSSELS,BELGIUM

[2] INST JULES BORDET,LAB INVEST CLIN HJ TAGNON,B-1000 BRUSSELS,BELGIUM

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1981年 / 17卷 / 12期

关键词：

D O I：

10.1016/0014-2964(81)90006-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1263 / 1266

页数：4

共 13 条

[1]

[Anonymous], 1979, WHO HDB REPORTING RE

[2] ANTI-TUMORAL EFFECT IN MICE OF A NEW TRIEPOXIDE DERIVATIVE - 1, 3, 5-TRIGLYCIDYL-S-TRIAZINETRIONE (NSC-296934) [J].

ATASSI, G ;

SPREAFICO, F ;

DUMONT, P ;

NAYER, P ;

KLASTERSKY, J .

EUROPEAN JOURNAL OF CANCER, 1980, 16 (12) :1561-1567

[3]

ATASSI G, 1980, CANCER CHEMOTHER P S, V5, P3

[4] PREPARATION AND PROPERTIES OF DIASTEREO-ISOMERIC 1,3,5-TRIGLYCIDYL-S-TRIAZINETRIONES [J].

BUDNOWSKI, M .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 1968, 7 (10) :827-+

[5]

CAVALLI F, 1981, P AM ASSOC CANC RES, V22, P191

[6]

DORR RT, 1980, P AM ASSOC CANC RES, V21, P299

[7]

ERICKSON LE, COMMUNICATION

[8] THROMBOPHILEBITIC POTENTIAL OF INTRAVENOUS CYTOTOXIC AGENTS [J].

HENNEY, JE ;

VONHOFF, DD ;

ROCZENCWEIG, M ;

MUGGIA, FM .

DRUG INTELLIGENCE & CLINICAL PHARMACY, 1977, 11 (05) :266-267

[9]

MYERS JW, 1981, P AM ASSOC CANC RES, V22, P174

[10]

ROZENCWEIG M, 1981, CANCER CLIN TRIALS, V4, P21

← 1 2 →